Dec. 19 at 5:47 PM
$LXRX Jardiance from deep pocketed Sales Team
$LLY also left Europe. They saw that
$AZN left, becuase of the DKA "Black Triangle" label they had to use on their T1D treatment. They feared this scary warning would confuse doctors on T2D and Hearth Failure Patients. AND THEY PULLED it from Europe too. Sanofi ditched on FDA rejection #1, despite EMA approval. Left Lexicon carrying the marketing expense bags. Could not market it, correct. But
$AZN felt the market was too low, or too little to endanger public relations for their larger pie: T2D and Heart Failure, for the same drug.
I'll admit. this is a FREE RIDE and Lexicon has NOTHING to lose, in getting approval. And patients LONG for non injection oral insulin treatment, maintenance for T1D. I get that. Jardiance from
$LLY and Forxiga from
$AZN were both rejected for T1D. So yes it would be a massive win, IF we get the Ketone Monitoring in place and approved. Still, the other three catalysts in my book are more than sufficient.
